Loading...
Loading...
ACRO BIOMEDICAL CO., LTD.
ACRO BIOMEDICAL CO., LTD.. Spoken Alpha tracks ACBM's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks ACBM's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 70% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ACBM.
curl https://api.spokenalpha.com/v1/companies/ACBM| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $5.43 | $3.77 | +44.1% | -6.2% | -4.4% |
| Q4 FY2026 | $4.92 | $3.67 | +34.1% | -7.4% | -10.2% |
| Q3 FY2026 | $5.00 | $3.62 | +38.0% | -2.0% | -3.1% |
| Q2 FY2026 | $5.09 | $3.88 | +31.1% | +0.7% | -1.0% |
| Q1 FY2025 | $5.02 | $3.64 | +37.9% | +2.3% | +1.5% |
| Q4 FY2025 | $5.29 | $3.80 | +39.1% | -5.0% | -5.7% |
| Q3 FY2025 | $4.96 | $3.73 | +33.0% | -7.9% | -9.5% |
| Q2 FY2025 | $5.35 | $3.77 | +41.8% | -5.3% | -3.5% |
| Q1 FY2024 | $5.02 | $3.81 | +31.7% | +1.9% | +0.1% |
| Q4 FY2024 | $5.03 | $3.80 | +32.5% | -4.9% | -5.6% |